| Hematologic malignancies and Li–Fraumeni syndrome M Swaminathan, SA Bannon, M Routbort, K Naqvi, TM Kadia, ... Molecular Case Studies 5 (1), a003210, 2019 | 62 | 2019 |
| The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients (Pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I … M Swaminathan, HM Kantarjian, N Daver, G Borthakur, M Ohanian, ... Blood 130 (Suppl 1), 723-723, 2017 | 62 | 2017 |
| A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome M Swaminathan, HM Kantarjian, M Levis, V Guerra, G Borthakur, ... Haematologica 106 (8), 2121, 2021 | 45 | 2021 |
| Menin inhibitors in acute myeloid leukemia—what does the future hold? M Swaminathan, W Bourgeois, SA Armstrong, ES Wang The Cancer Journal 28 (1), 62-66, 2022 | 32 | 2022 |
| Novel therapies for AML: a round-up for clinicians M Swaminathan, ES Wang Expert Review of Clinical Pharmacology 13 (12), 1389-1400, 2020 | 32 | 2020 |
| A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis P Bose, M Swaminathan, N Pemmaraju, A Ferrajoli, EJ Jabbour, ... Leukemia & lymphoma, 2019 | 26 | 2019 |
| Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy A Singh, N Mencia-Trinchant, EA Griffiths, A Altahan, M Swaminathan, ... JCO Precision Oncology 6, e2100309, 2022 | 18 | 2022 |
| A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure M Swaminathan, G Borthakur, TM Kadia, A Ferrajoli, Y Alvarado, ... Leukemia & lymphoma, 1-7, 2019 | 15 | 2019 |
| A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure M Swaminathan, G Borthakur, TM Kadia, A Ferrajoli, Y Alvarado, ... Leukemia & lymphoma, 1-7, 2019 | 15 | 2019 |
| Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia M Swaminathan, JE Cortes Therapeutic Advances in Hematology 14, 20406207231154708, 2023 | 12 | 2023 |
| Unique case of myeloproliferative neoplasm with two rare clonal abnormalities: rare JAK2 exon 12 mutation and rare e14a3 (b3a3) BCR/ABL fusion transcript M Swaminathan, KP Patel, J Huynh-Lu, G Tang, Z Zuo, R Miranda, ... Acta haematologica 141 (1), 23-27, 2019 | 7 | 2019 |
| Renal cell carcinoma presenting as pleural effusion A Arain, M Swaminathan, J Kumar WMJ 118, 49-51, 2019 | 6 | 2019 |
| FOXC1 expression in acute myeloid leukemia: potential predictor of disease relapse and/or refractory disease M Swaminathan, TW Jensen, T Ray, ND Andruska, A Shah, JR Egner, ... Blood 128 (22), 5260, 2016 | 5 | 2016 |
| Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study A Bataller, G Montalban-Bravo, A Bazinet, Y Alvarado, K Chien, ... The Lancet Haematology 11 (3), e186-e195, 2024 | 3 | 2024 |
| DNMT3A and TET2 mutant clonal hematopoiesis may drive a proinflammatory state and predict enhanced response to immune checkpoint inhibitors AS Singh, N Mencia-Trinchant, EA Griffiths, M Swaminathan, M Gravina, ... Blood 138, 4295, 2021 | 3 | 2021 |
| Clinical Heterogeneity of AML Is Associated with Mutational Heterogeneity M Swaminathan, K Morita, Y Yuanqing, F Wang, JK Burks, C Gumbs, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 3 | 2018 |
| Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data N Jain, MJ Keating, PA Thompson, A Ferrajoli, J Senapati, JA Burger, ... Blood 142, 4635, 2023 | 2 | 2023 |
| Efficacy of ponatinib after multiple lines of therapy for chronic myeloid leukemia M Swaminathan, HM Kantarjian, K Sasaki, F Ravandi, G Borthakur, ... Blood 132, 3013, 2018 | 2 | 2018 |
| A case of May-Thurner syndrome E Calvaresi, M Swaminathan, J Jokela Carle selected papers 59 (1), 46, 2016 | 2 | 2016 |
| A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia PJ Hampel, M Swaminathan, KA Rogers, EM Parry, JA Burger, MS Davids, ... Blood Advances, 2024 | 1 | 2024 |
